Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is primarily used as an anti-diabetic medication, but recent evidence suggests its potential role in promoting weight loss individuals without diabetes. A comprehensive literature review was conducted, analysing relevant studies published between 2013-2021, focusing on the efficacy and safety of canagliflozin for non-diabetic p...

Type 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder, which affects more than 300 million people globally. The common effect of uncontrolled diabetes is the state of hyperglycemia, which results from beta-cell dysfunction as well as insulin resistance, which is accompanied with microvascular and macrovascular complications. As hyperglycemia defines diabetes, glycemic control is fun...

We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes nephropathy according prior history heart failure Canagliflozin Renal Events Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. found that participants a at baseline (15%) were more likely be older, female, white, have atherosclerotic cardiovascular disease, use diuretics beta b...

The prevalence of type 2 diabetes mellitus (T2DM) is rising in Australia. Sodium glucose co-transporter 2 (SGLT2) inhibitors are an emerging treatment for T2DM. SGLT2 inhibitors offer a novel approach to lowering hyperglycaemia by suppressing renal glucose reabsorption and increasing urinary glucose excretion. The increased urinary glucose excretion has also been associated with caloric loss an...

Background: Obesity is a risk factor for insulin resistance, dyslipidemia, fatty liver disease, and all disorders associated with metabolic syndrome. Here we evaluated the association of glucagon-like peptide 1 (GLP-1) analog, liraglutide, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, canagliflozin, on improvement syndrome symptoms in high-fat diet (HFD)-induced obesity rat model. Methods:...

656 P&T® • November 2013 • Vol. 38 No. 1

According to Polish HTA guidelines, a systematic literature review was conducted in which data on comparative efficacy and safety of canagliflozin and NPH insulin were searched. As no head-to-head trial comparing canagliflozin with NPH insulin were identified, mixed treatment comparison analysis was conducted (following Polish HTA guidelines). Two RCTs assessing effectiveness of canagliflozin i...

INTRODUCTION Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are relatively new antihyperglycemic agents that lower renal glucose reabsorption. They are used as adjunctive therapy to standard diabetes treatment. CASE REPORT We present the case of a 62-year-old woman with a past medical history of type 2 diabetes mellitus and sudden-onset diabetic ketoacidosis (DKA). Use of canagliflozin, ...

Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced glycated hemoglobin (A1C), body weight (BW), and systolic blood pressure (SBP) and are associated wi...

Rationale & Objective Canagliflozin reduces the risk for cardiovascular and kidney outcomes in type 2 diabetes. This study aimed to assess relative absolute effects of canagliflozin on clinical across different KDIGO (Kidney Disease: Improving Global Outcomes) categories based estimated glomerular filtration rate (eGFR) urinary albumin-creatinine ratio. Study Design Post hoc analysis CANagliflo...